Kate Fife

5.4k total citations
64 papers, 1.9k citations indexed

About

Kate Fife is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Kate Fife has authored 64 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 24 papers in Molecular Biology. Recurrent topics in Kate Fife's work include Renal cell carcinoma treatment (30 papers), Cancer Genomics and Diagnostics (11 papers) and Renal and related cancers (10 papers). Kate Fife is often cited by papers focused on Renal cell carcinoma treatment (30 papers), Cancer Genomics and Diagnostics (11 papers) and Renal and related cancers (10 papers). Kate Fife collaborates with scholars based in United Kingdom, United States and France. Kate Fife's co-authors include Mark Bower, John F. Thompson, Graham Stevens, Christine Parkinson, Pippa Corrie, Michal J. Besser, G. W. Milton, Dominic H. Moon, Karin Petersen-Schaefer and Kerwin F. Shannon and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Kate Fife

60 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kate Fife United Kingdom 22 884 859 718 499 312 64 1.9k
Karen Dresser United States 29 616 0.7× 1.0k 1.2× 605 0.8× 248 0.5× 220 0.7× 75 2.7k
Julian Kim United States 18 727 0.8× 542 0.6× 157 0.2× 353 0.7× 339 1.1× 45 1.9k
Imad A. Tabbara United States 21 1.4k 1.6× 499 0.6× 224 0.3× 243 0.5× 201 0.6× 65 2.5k
Francesco Spagnolo Italy 27 1.7k 1.9× 951 1.1× 421 0.6× 184 0.4× 100 0.3× 111 2.5k
Katharina C. Kähler Germany 22 2.5k 2.8× 603 0.7× 444 0.6× 363 0.7× 141 0.5× 79 2.9k
John P. Geisler United States 27 563 0.6× 684 0.8× 279 0.4× 292 0.6× 63 0.2× 99 2.3k
Francesca Sanguedolce Italy 28 547 0.6× 700 0.8× 744 1.0× 159 0.3× 65 0.2× 167 2.3k
Ta‐Chung Chao Taiwan 22 724 0.8× 317 0.4× 485 0.7× 92 0.2× 128 0.4× 99 1.4k
Manfred Ratschek Austria 28 688 0.8× 973 1.1× 766 1.1× 185 0.4× 207 0.7× 100 2.6k
Milan J. Anadkat United States 22 733 0.8× 276 0.3× 289 0.4× 227 0.5× 669 2.1× 68 1.8k

Countries citing papers authored by Kate Fife

Since Specialization
Citations

This map shows the geographic impact of Kate Fife's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate Fife with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate Fife more than expected).

Fields of papers citing papers by Kate Fife

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate Fife. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate Fife. The network helps show where Kate Fife may publish in the future.

Co-authorship network of co-authors of Kate Fife

This figure shows the co-authorship network connecting the top 25 collaborators of Kate Fife. A scholar is included among the top collaborators of Kate Fife based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate Fife. Kate Fife is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Fife, Kate, et al.. (2024). Variability in Kidney Cancer Treatment and Survival in England: Results of a National Cohort Study. Clinical Oncology. 36(11). e429–e438. 2 indexed citations
3.
Fife, Kate, et al.. (2023). Single-Fraction Stereotactic Ablative Body Radiotherapy for Primary and Extracranial Oligometastatic Cancers. Clinical Oncology. 35(12). 773–786. 2 indexed citations
4.
Venugopal, Balaji, Manon Pillai, Thomas Powles, et al.. (2021). Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes. Clinical Genitourinary Cancer. 20(1). 94–94.e10. 6 indexed citations
5.
Corrie, Pippa, Sarah J. Welsh, Grant D. Stewart, et al.. (2021). Identification of a microbiome signature predicting immune checkpoint inhibitor outcomes across multiple cancer types in the MITRE study.. Journal of Clinical Oncology. 39(15_suppl). TPS2665–TPS2665. 1 indexed citations
6.
Fife, Kate, et al.. (2021). Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe. Frontiers in Oncology. 11. 672021–672021. 5 indexed citations
7.
Rembielak, Agata, Andrew Sykes, Kate Fife, Amarnath Challapalli, & Jenny Nobes. (2020). Radiotherapy and Systemic Treatment for Non-melanoma Skin Cancer in the COVID-19 Pandemic. Clinical Oncology. 32(7). 417–419. 4 indexed citations
8.
Keohane, Stephen, P.G. Budny, O.M. Dolan, et al.. (2020). British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020*. British Journal of Dermatology. 184(3). 401–414. 56 indexed citations
9.
Hawkins, Robert D., Kate Fife, Meng Wang, et al.. (2020). Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK. BMC Cancer. 20(1). 670–670. 11 indexed citations
10.
11.
Fife, Kate & Andrew Bang. (2020). Combined Radiotherapy and New Systemic Therapies – Have We Moved Beyond Palliation?. Clinical Oncology. 32(11). 758–765. 8 indexed citations
12.
Moran, Michael, et al.. (2019). Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data. Targeted Oncology. 14(4). 405–416. 43 indexed citations
13.
14.
Fife, Kate, R. M. Herd, Susan Lalondrelle, et al.. (2016). Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma. Future Oncology. 13(2). 175–184. 22 indexed citations
15.
Basset‐Séguin, Nicole, Axel Hauschild, Jean‐Jacques Grob, et al.. (2015). Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. The Lancet Oncology. 16(6). 729–736. 170 indexed citations
16.
Ajithkumar, Thankamma, Christine Parkinson, Kate Fife, Pippa Corrie, & Sarah Jefferies. (2015). Evolving treatment options for melanoma brain metastases. The Lancet Oncology. 16(13). e486–e497. 65 indexed citations
17.
Spathis, Anna, Kate Fife, Fiona Blackhall, et al.. (2014). Modafinil for the Treatment of Fatigue in Lung Cancer: Results of a Placebo-Controlled, Double-Blind, Randomized Trial. Journal of Clinical Oncology. 32(18). 1882–1888. 78 indexed citations
18.
Lear, John T., Peter Dziewulski, Kate Fife, et al.. (2014). Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. British Journal of Cancer. 111(8). 1476–1481. 74 indexed citations
19.
Bower, Mark, et al.. (1999). HAART PROLONGS TIME TO TREATMENT FAILURE (TTF) IN KAPOSI'S SARCOMA (KS).. JAIDS Journal of Acquired Immune Deficiency Syndromes. 21(1). A24–A24. 11 indexed citations
20.
Fife, Kate, et al.. (1992). Chylous ascites in Kaposi's sarcoma: a case report. British Journal of Dermatology. 126(4). 378–379. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen Dresser Breakdown of academic impact, for papers by Julian Kim Breakdown of academic impact, for papers by Imad A. Tabbara Breakdown of academic impact, for papers by Francesco Spagnolo Breakdown of academic impact, for papers by Katharina C. Kähler Breakdown of academic impact, for papers by John P. Geisler Breakdown of academic impact, for papers by Francesca Sanguedolce Breakdown of academic impact, for papers by Ta‐Chung Chao Breakdown of academic impact, for papers by Manfred Ratschek Breakdown of academic impact, for papers by Milan J. Anadkat
Rankless by CCL
2026